Bio4t2's science is fueling new developments in CAR-T therapies for solid tumors, that previously held-back the field. PrismCore is able to produce CARs that are architecturally optimized to instill in T cells antigen density dependent response. The calibrated CAR-T specifically bind to self-antigens when they are over-expressed on the surface of malignant cells with the promise of a therapeutic effect.
